Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

179
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
179
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

185
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
185
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

160
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
160
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

121
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
121
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

588
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
588
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

163
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
163

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transition practices of patients with inflammatory bowel disease from pediatric to adult healthcare systems. Results from a national survey.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same author

Incidence and Neoplastic Risk Associated with Colonic Stricture in Paediatric-Onset Crohn's Disease: A Population-based Study.

Clinics and research in hepatology and gastroenterology·2026
Same author

Long-term outcomes of children with ulcerative colitis after acute severe colitis: A GETAID pédiatrique multicenter study.

Journal of pediatric gastroenterology and nutrition·2026
Same author

Basophils drive the resolution and promote wound healing in adult and aged mice.

The Journal of experimental medicine·2026
Same author

Intentions, practices, and social representations regarding breastfeeding among women experiencing social disadvantage: findings from the qualitative component of the ECAIL trial.

International breastfeeding journal·2026
Same author

Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial.

The lancet. Gastroenterology & hepatology·2026
Same journal

Calendar of Courses, Symposiums and Conferences.

The American journal of gastroenterology·2026
Same journal

Molecular Nonendoscopic Tests for the Early Detection of Esophageal Squamous Carcinoma and High-Grade Dysplasia: Promising Progress.

The American journal of gastroenterology·2026
Same journal

ACG Clinical Guideline: Colonic Diverticulitis.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: July 2026.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: July 2026.

The American journal of gastroenterology·2026
Same journal

2026 CME Information.

The American journal of gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Jul 31, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K

New Therapeutic Strategies Are Associated With a Significant Decrease in Colectomy Rate in Pediatric Ulcerative

Delphine Ley1,2, Ariane Leroyer2,3, Claire Dupont4

  • 1Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, CHU Lille, Lille, France.

The American Journal of Gastroenterology
|May 4, 2023
PubMed
Summary
This summary is machine-generated.

The introduction of immunosuppressants (IS) and antitumor necrosis factor (TNF) therapies significantly reduced colectomy risk in pediatric ulcerative colitis (UC) patients. However, flare-related hospitalizations increased with these advanced treatments.

More Related Videos

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

216
Transplantation of Adipose Tissue-Derived Stem Cell Sheet to Reduce Leakage After Partial Colectomy in A Rat Model
09:58

Transplantation of Adipose Tissue-Derived Stem Cell Sheet to Reduce Leakage After Partial Colectomy in A Rat Model

Published on: August 11, 2018

7.6K

Related Experiment Videos

Last Updated: Jul 31, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

216
Transplantation of Adipose Tissue-Derived Stem Cell Sheet to Reduce Leakage After Partial Colectomy in A Rat Model
09:58

Transplantation of Adipose Tissue-Derived Stem Cell Sheet to Reduce Leakage After Partial Colectomy in A Rat Model

Published on: August 11, 2018

7.6K

Area of Science:

  • Pediatric Gastroenterology
  • Inflammatory Bowel Disease Research
  • Clinical Outcomes Analysis

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease affecting children.
  • Long-term outcomes in pediatric UC have been influenced by evolving treatment paradigms.
  • Understanding the impact of immunosuppressants (IS) and antitumor necrosis factor (TNF) therapies is crucial.

Purpose of the Study:

  • To evaluate the long-term effects of IS and anti-TNF introduction on pediatric-onset UC outcomes.
  • To compare disease progression and treatment outcomes across different eras of therapy.
  • To analyze population-level trends in colectomy, disease extension, and hospitalization.

Main Methods:

  • Retrospective analysis of a large, population-based pediatric UC cohort (EPIMAD registry).
  • Patients diagnosed before age 17 between 1988 and 2011 were followed until 2013.
  • Comparison of outcomes across three diagnostic periods: pre-IS, pre-anti-TNF, and anti-TNF eras.

Main Results:

  • IS and anti-TNF use increased significantly over time, reaching 63.8% and 37.2% by 5 years in the latest era.
  • The 5-year risk of colectomy decreased significantly from 17% in the pre-IS era to 9% in the anti-TNF era (P=0.013).
  • Flare-related hospitalizations at 5 years significantly increased from 16% to 42% (P=0.0004) with newer therapies.

Conclusions:

  • Increased use of IS and anti-TNF therapies is associated with a substantial reduction in colectomy rates for pediatric UC.
  • While colectomy risk decreased, the risk of flare-related hospitalizations rose, indicating a complex treatment benefit-risk profile.
  • These findings highlight the evolving landscape of pediatric UC management and its population-level impact.